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Poxviruses are DNA viruses that express numerous
proteins to subvert the host immune response.
Vaccinia virus protein K7 adopts a Bcl-2 fold and
displays structural and functional similarities to
Toll-like receptor antagonist A52. Both proteins
interact with IRAK2 and TRAF6 and suppress TLR-
dependent NF-kB activation. However, unlike A52,
K7 also forms a complex with RNA helicase DDX3
and antagonizes interferon-b promoter induction.
We have narrowed the K7 binding site to an
N-terminal peptide motif of DDX3 ahead of its core
RNA-helicase domains. The crystal structure of full-
length K7 in complex with the DDX3 peptide reveals
a thumblike projection of tandem phenalyalanine
residues of DDX3 into a deep hydrophobic cleft.
Mutagenesis of these phenylalanines abolishes the
effects of DDX3 on interferon-b promoter induction.
The structure of K7-DDX3 reveals a novel binding
mode by a viral Bcl-2 protein that antagonizes
a key pathway in innate immunity.
INTRODUCTION
The innate immune system is critical for the detection of invading
pathogens and generation of the early inflammatory response.
Pattern recognition receptors (PRRs), such as Toll-like/inter-
leukin-1 receptors (TLRs) and RIG-like helicases (RLHs), recog-
nize distinct molecular patterns on viruses and bacteria (O’Neill,
2006; Takaoka and Taniguchi, 2008). TLR and RLH engagement
results in complex downstream signaling cascades involving
adaptor proteins and kinases, ultimately leading to activation
of the transcription factors NF-kB and interferon regulatory
factors (IRFs) 3 and 7. This activation subsequently leads to
the release of proinflammatory cytokines and type I interferons
(Moynagh, 2005). Stimulation of TLR3, TLR4, and RLH leads to
downstream activation of the kinases TBK1 and IKK3, which is
essential for activation of IRF3/IRF7 and subsequent interferon
b (IFN-b) promoter induction.
Poxviruses are large double-stranded DNA viruses that have
evolved numerous mechanisms for evasion of innate immune
signaling pathways. Vaccinia virus (VACV), the prototypical
member of the Poxviridae family that is used for the smallpox
vaccine, replicates within the cytosol of infected cells and1528 Structure 17, 1528–1537, November 11, 2009 ª2009 Elsevier Lencodes over 200 open reading frames (Smith et al., 1991).
During poxvirus infection, several viral proteins are expressed
in the cytosol that antagonize the inflammatory response and
favor viral replication (Bowie and Unterholzner, 2008). In partic-
ular, VACV proteins A46 and A52 were shown to specifically
antagonize TLR signaling (Bowie et al., 2000; Harte et al.,
2003; Maloney et al., 2005; Stack et al., 2005). The discovery
of this viral evasion strategy provided early evidence for a role
of TLRs in the antiviral immune response. A46 contributes to
virulence by targeting multiple TLR adaptor proteins, resulting
in membrane-proximal inhibition of TLR signaling and suppres-
sion of NF-kB and IRF3 activation (Bowie and Unterholzner,
2008; Stack et al., 2005). A52 acts further downstream and
inhibits NF-kB activation by targeting IRAK2 (Harte et al., 2003;
Keating et al., 2007; Maloney et al., 2005). In addition, binding
of A52 to TRAF6 mediates p38 MAP kinase activation and
enhances TLR-mediated activation of the anti-inflammatory
cytokine IL-10 (Maloney et al., 2005).
VACV protein K7 has 20% overall sequence identities to A52.
Both K7 and A52 interact with TRAF6 and IRAK2 and inhibit TLR-
induced NF-kB activation (Schroder et al., 2008). However,
unlike A52, K7 binds to human DEAD-box RNA helicase DDX3
and inhibits TLR-dependent and -independent IRF3/7 activation
and induction of the IFN-b promoter. The investigation of this K7-
mediated viral evasion strategy led to the discovery of a novel
role for DDX3 in innate immunity (Schroder et al., 2008). DDX3
binds to and is phosphorylated by IKK3 and/or TBK1 (Schroder
et al., 2008; Soulat et al., 2008), the two kinases that are essential
for IRF3/IRF7 activation. Following PRR stimulation of innate
immune signaling, DDX3 enhances IRF3 activation and IFN-b
induction (Schroder et al., 2008; Soulat et al., 2008). K7 binding
to DDX3 interferes with the activation of IRF3/IRF7 and subse-
quent induction of the IFN-b promoter. DDX3 appears to have
multiple cellular functions and has previously been implicated
in transcriptional and translational control of gene expression,
RNA splicing and export, and cell cycle control (Rosner and Rin-
kevich, 2007). Hepatitis B virus (HBV), hepatitis C virus (HCV),
and human immunodeficiency virus (HIV) also express proteins
that interact with DDX3 during their replication cycle (Ariumi
et al., 2007; Kwong et al., 2005; Wang et al., 2009). The Y
chromosome-encoded DDX3Y isoform is highly conserved
throughout its amino acid sequence with DDX3X, the subject
of this study. However, DDX3Y gene expression is restricted to
male reproductive organs, where it is essential for spermatogen-
esis (Lardone et al., 2007).
Recent structural work has provided some insight into the
molecular basis for poxvirus antagonism of innate immunity.td All rights reserved
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Structure of K7-DDX3The crystal structures of VACV proteins A52, B14, and N1
revealed that they adopt an a-helical Bcl-2 fold. However, these
proteins are devoid of sequence similarities to each other and to
viral and cellular members of this superfamily (Cooray et al.,
2007; Graham et al., 2008). Similarly, the NMR structure of
VACV protein K7 also revealed a Bcl-2 fold, but in contrast to
the other VACV proteins, K7 was found to be a monomer in solu-
tion (Kalverda et al., 2009). Viral and cellular Bcl-2 proteins regu-
late cell death by forming hetero-oligomers via a surface groove
that binds to a-helical BH3 motifs of partner Bcl-2 proteins. The
groove is formed by helices a2-a5 and is observed in various
conformational states, ranging from ‘‘open’’ to ‘‘closed’’ in the
absence of BH3 ligands (Day et al., 2005; Day et al., 2008; Kvan-
sakul et al., 2007; Liu et al., 2003a; Petros et al., 2001; Sattler
et al., 1997). The groove is ‘‘open’’ in the ligand-bound state of
conventional Bcl-2 proteins that regulate apoptosis, thus
enabling intimate hydrophobic contacts with amphipathic BH3
a helices (Kvansakul et al., 2007; Liu et al., 2003b; Petros
et al., 2004; Sattler et al., 1997).
The structures of K7, A52, and B14 revealed a closed BH3
groove that is apparently incompatible with binding to a-helical
BH3 motifs, because these three viral proteins do not regulate
apoptosis (Graham et al., 2008; Schroder et al., 2008). Our
previous biochemical studies showed that K7 recognizes
a segment of DDX3 (residues 61–90) that is upstream of the
conserved tandem RecA-like helicase domains (residues 168–
576) (Kalverda et al., 2009). This region correlates with a func-
tional role for the DDX3 N terminus (residues 1–139) in the induc-
tion of the IFN-b promoter (Schroder et al., 2008), suggesting
that K7 binds to the region of DDX3 that mediates this effect.
The N terminus of DDX3X (1–139), the X chromosome isoform
of DDX3, is enriched in serine residues (27), glycine (20), and
charged amino acids (25 Lys+Arg+His; 22 Asp+Glu). This
segment of DDX3 is presumably unstructured and is not
conserved in other RNA helicases or known proteins in sequence
databases. This N-terminal segment was removed in the pub-
lished crystal structure of DDX3, which was determined using
the fragment 168–582 (Hogbom et al., 2007).
Despite the identification of numerous cellular targets of
VACV proteins, there is currently little structural information
regarding the protein-protein complexes formed during infec-
tion. The only structure of a poxvirus Bcl-2 protein with its target
involves a BH3 peptide from Bak, which binds to the canonical
BH3 groove of myxoma M11 protein (Kvansakul et al., 2007).
Intriguingly, K7 and A52 share similar three-dimensional struc-
tures and common cellular targets, but A52 is unable to bind
DDX3 (Schroder et al., 2008). Here, we have identified a peptide
motif in the N-terminal region of DDX3, ahead of the core RNA
helicase domains, that largely retains the binding affinity to
K7. The crystal structure of full-length 149-residue K7 in com-
plex with a 20-residue DDX3 peptide (residues 71–90) has
been determined by single-wavelength anomalous diffraction
(SAD) methods. The complex reveals the molecular basis for
K7-DDX3 specificity via a binding mode that is novel within
the Bcl-2 superfamily. We identify key residues that mediate
the interaction between DDX3 and K7 and demonstrate that
a tandem phenylalanine motif in DDX3 that is sequestered by
K7 is also required for IRF3 activation and IFN-b promoter
induction.Structure 17, 1528–15RESULTS
K7-Interacting Region of DDX3
The N-terminal region of DDX3 (1–167) was presumed to be
unstructured, and a circular dichroism (CD) analysis supports
this prediction (see Figure S1 available online). Previous trunca-
tions of DDX3 had minimized the K7-binding region to 30 resi-
dues (61–90) (Kalverda et al., 2009). The interacting region was
further narrowed using a series of overlapping DDX3 peptides
(Figure 1). All peptides were synthesized with a hexahistidine-
tag at the N terminus to facilitate a pull-down assay with purified,
untagged K7. The results indicate that DDX3 segment 81–90 is
necessary for binding to K7 (Figure 1). Isothermal titration calo-
rimetry experiments confirmed that DDX3 peptides encompass-
ing the segment 81–90 largely retained the affinity of a nearly
complete fragment of DDX3 (5–580) that included the N terminus
and the two RecA-like domains (Figure 2). Consequently,
peptides 61–90, 71–90, and 81–100 lacking the hexahistidine
tag were synthesized, because these were deemed suitable for
cocrystallization with K7. The best crystals were obtained with
peptide 71–90, and, following selenomethionine derivitization
of K7, the crystal structure of K7-DDX3 was solved by SAD
methods.
Figure 1. Biochemical Mapping of the Interaction Between K7 and
DDX3
Previous work had mapped the K7-interacting region to residues 61–90 of
DDX3. Smaller overlapping His-tagged peptides were used to pull down
untagged K7 and visualize the protein by Coomassie blue stain. The lane
marked ‘‘+thr’’ denotes K7 treated with thrombin, which migrates at 16 kDa.
This protein was subjected to further purification by a second Ni2+-agarose
column (lane FT). In the negative control lane (-), Ni2+, but not peptide, was
added to K7. Only those Hi-tagged peptides spanning the region 81–90 of
DDX3were able to pull down K7. The sequence of this region of DDX3 is shown
for convenience. The peptides are approximately 2–3 kDa in size and are too
small to be visualized in these SDS-PAGE gels.37, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1529
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Structure of K7-DDX3Structure of K7
The final model of K7-DDX3 was refined using data to 1.6 A˚
and includes residues 6–149 of K7, 82–88 of DDX3, and 261
Figure 2. Isothermal Titration Calorimetry
of K7-DDX3 Complex Formation
(A) Full-length K7 (400 mM) was injected into
DDX35–580 (30 mM) in the sample cell.
(B) DDX3 peptide 71–90 (250 mM) was injected
into the cell containing full-length K7 (30 mM).
Data were fit using Origin software version 7.0.
The Kd was 510 nM for the fragment 5–580 and
was modestly weaker for the peptide 71–90
(930 nM), demonstrating that this peptide largely
retains its affinity to K7. The stoichiometry
deduced from data fitting is close to 1 for both
titrations shown. The thermodynamic parameters
are summarized in Table 1.
Figure 3. Structure of K7-DDX3 Complex
K7 is shown in blue ribbons, and the peptide 82–88
is a yellow stick model. Canonical Bcl-2 family
nomenclature is used for a helices, although K7
lacks a4 and a6.
water molecules (Figures 3 and 4). Con-
sistent with the uncomplexed NMR struc-
ture, K7 adopts an a-helical topology
belonging to the Bcl-2 family that con-
sists of a core of seven a helices.
However, K7 is a noncanonical member
of the Bcl-2 family in several respects.
First, K7 is a monomer, whereas the other VACV proteins—
A52, B14, and N1—are dimers (Aoyagi et al., 2007; Cooray
et al., 2007; Graham et al., 2008; Kalverda et al., 2009). As1530 Structure 17, 1528–1537, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
Structure
Structure of K7-DDX3α1 α2
α5 α6 α7
α3
K7    1 MATKLDYEDAVFYFVDDDKICSRDSIIDLIDEYITWRNHVIVFNKDITSCGRLYKELMKFDDVAIRYYGIDKINEIVEAMSEG-83 
A52  16.VTTRRENEERKKY.LEYDDLLDRDEMFTILEEYFMYRGLLGLR IKYGRLFNEIKKFDNDAEEQFGIEELKQKLRLNSE-109 
M11L                         2-MSRLKTAVYDYLNDVDITEC(21).(26)LLCQLSNCCDFINETY....LYDIMERDIL-57
Bcl-xL        1-MSQSNRELVVDFLSKLS(28)......(87)KQALREAGDEFELRY.RRAFSDLTSQLHI-114
B14                           26-VRQCLTEYIYWSSYAYRN.......GQLYSTLLSFRDDAELVFID..IRELVKNM-75
N1           1-MRTLLIRYILWRNDNDQTYYN DDFKKLMLLDELVDD    GDVCTLIKNMRMT-49 
K7   DHYINFTKVHD QESLFATIGICAKITEHWGYKKISESRFQSLGNITDLMTDDNINILILFLEKKLN-149
A52 ..DNFIDYIKVQKQDIV.TVYDCISMIGLCACVVDVWRNEKLF-SRWKYCLRAIKLFINDHMLDKIKSILQNRLVYVEMS-190 
M11L .VNIKNTLTFALRDA SPSVKLATLTLLASVIKKLNKIQHT DAAMFSEVIDGI  VAEEQQVIGFIQKKCK-128
Bcl-xL .FEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIASWMATYLNDHL.ENGGWDTFVDLYG-196
B14  ..DVKDCAEIIRCYI..TIREISAIIGLCAYAATYWGGEDHPTSNSLNALFVMLEMLNYVDYNIIFRRMN-149    
N1  ..GPLLDRLNQPVN    NIEDAKRMIAISAKVARDIGERS EIRWEESFTILFRMIE-TYFDDLMIDLY-115
α4
Figure 4. Structure-Based Sequence Alignment of Poxvirus Bcl-2 Proteins
Structures were aligned using a secondary structure matching algorithm in COOT (Emsley and Cowtan, 2004), and the alignment was manually adjusted where
necessary. Green residues are conserved between K7 and A52. The gray shading indicates conservation of the hydrophobic core in the Bcl-2 family, despite the
absence of sequence identities. Red dots mark DDX3-interacting residues of K7.a consequence, an additional surface is exposed in K7 that is
critical for DDX3 binding (see below). Second, two of the seven
canonical a helices (a4 and a6) are nonhelical in K7. The atypical
conformation of these two segments of K7 is necessary to form
a deep hydrophobic pocket to accommodate the DDX3 peptide.
Third, the canonical groove that binds to BH3 domains of cellular
proapoptotic Bcl-2 proteins is closed in K7. Unlike conventional
Bcl-2 homologs, K7 does not antagonize innate cell death path-
ways. In this latter respect, K7 resembles VACV proteins A52 and
B14, whose crystal structures were recently determined (Gra-
ham et al., 2008). K7 and A52 share 27% sequence identities
(54% homology) within their core Bcl-2 domain, and both
proteins have a closed BH3 groove. Upon superposition of K7
and A52 secondary structures, the root-mean-square (rms) devi-
ation (rmsd) of 108 aligned Ca atoms is 1.89 A˚. Apart from A52,
the closest structural relative of K7 is VACV protein N1 (PDB
code 2i39; 2.0 A˚ rmsd over 96 residues). N1 is a conventional
antiapoptotic protein with an open BH3 groove that interacts
with cellular Bcl-2 proteins Bad, Bax, and Bid (Cooray et al.,
2007). K7 and A52 are devoid of significant sequence identities
to N1, B14, and other viral and cellular Bcl-2 proteins (Figure 5).Structure 17, 1528–1Nevertheless, K7, A52, and B14 share a Bcl-2 scaffold with
a closed BH3 groove and antagonize distinct immune signaling
pathways.
Structure of the K7-DDX3 Complex
The DDX3 peptide binds to a negatively charged face of K7 and
protrudes into a deep hydrophobic pocket (Figures 4–6). Resi-
dues 82–88 of DDX3 are ordered in both molecules of the asym-
metric unit and have an identical conformation. The bound DDX3
peptide segment is entirely consistent with our in vitro pull-down
assays and thermodynamic studies. The hydrophobic binding
pocket in K7 is bordered by the N terminus (Tyr7), a1, and the
region 118–127, which is predominantly nonhelical but is labeled
‘‘a6’’ to remain consistent with the canonical Bcl-2 fold. Despite
lacking secondary structure, the backbone in this segment is
well ordered in electron density maps. A52, which is the closest
relative of K7, is a-helical (a6) in this corresponding segment
(residues 154–168; Figures 4 and 7). Strikingly, the dimeric inter-
face of A52 comprises a1, a6, and the N terminus, which maps
directly onto the DDX3-binding site of K7. All of the known
VACV Bcl-2-family proteins are homodimers, and the dimericFigure 5. Refined Electron Density of the
K7-DDX3 Complex
The map (2Fo-Fc) was calculated using all atoms
and is contoured at 1.5 s. The electron density
around the peptide is colored yellow to distinguish
it from K7, using the program Pymol.537, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1531
Structure
Structure of K7-DDX3Figure 6. Electrostatic Surface View of K7 in Divergent Stereo
The peptide is represented as a stick model. Stereo rendering reveals the depth of penetration by Phe85 into the K7 pocket.interface is broadly conserved in the superfamily (Graham et al.,
2008). In contrast, K7 is a monomer, and this face is therefore
free to interact with DDX3. Furthermore, this face of K7 has
a predominantly negatively charged character that is comple-
mentary to positively charged DDX3. The overall pI of K7 is
4.8, whereas the N-terminal segment of DDX3 (1–143) preceding
the a-helical ‘‘flanking region’’ (residues 144–167) and core heli-
case domains has a pI of 7.8 (Hogbom et al., 2007; Sengoku
et al., 2006).
The conformation of the bound peptide begins with an
extended segment (Ser82–Ser83), followed by a loop that is
anchored at the tip by two phenylalanine side chains, Phe84
and Phe85. Strikingly, the insertion of these aromatic residues
into a deep hydrophobic cleft effectively means that the DDX3
peptide occupies the position of a6 in the canonical Bcl-2 fold.
The intimate association of K7-DDX3 is reflected in hydrogen
bonds between the side chain of Asp87 and the backbone
amides of Ile128 and Thr129, which nucleate a single turn a helix
(a6). Asp87 also forms a hydrogen bond with the side chain
of Thr129, further stabilizing the conformation of K7 at the
N terminus of a6. The peptide conformation is stabilized by
two internal hydrogen bonds. The first involves Ser83(Og) and
the backbone amide of Phe85. The second internal hydrogen
bond (3.4 A˚) comprises the backbone of Phe85(CO) and the
backbone amide of Arg88 that is reminiscent of an a-helical
310 hydrogen bond. The N and C termini of the peptide approach
close in space such that the a-carbon atoms of Ser82 and Arg881532 Structure 17, 1528–1537, November 11, 2009 ª2009 Elsevierare within 6 A˚. Thus, the overall peptide adopts a thumblike
projection into a hydrophobic pocket of K7. The peptide is likely
disordered in solution, as evidenced by CD spectroscopy of the
fragment 5–167 of DDX3 (Figure S1). Furthermore, a second K7-
binding site for the peptide reveals a completely different confor-
mation for the diphenyl motif. This second site is situated on the
surface of molecule B in the asymmetric unit and mediates
crystal contacts along the layer aligned with the AC face of the
monoclinic lattice (Figure S2). Although this second site is not
biologically relevant, the variable conformation of the peptide
adopted during crystallization suggests significant flexibility in
solution, prior to complex formation with K7.
Interactions between K7 and the DDX3 peptide involve hydro-
phobic contacts, hydrogen bonds, and electrostatic interac-
tions. The packing of the diphenyl motif of DDX3 completes
the central piece of a continuous stretch of K7 aromatic residues
comprising Phe43, Tyr7, Phe122, and Phe89. The key determi-
nant of electrostatic complementarity is Arg88 of DDX3, which
forms salt bridges to both Asp28 and Asp31 (Od2). Asp31
(Od1) is also hydrogen bonded to DDX3 residue Ser83 (Og). A
total of 545 A˚2 of K7 is buried in the complex, whereas 126 A˚2
(30% of total surface area) of the DDX3 peptide becomes buried
after complex formation. Superposition of the uncomplexed
NMR structure of K7 with the bound complex reveals significant
flexibility around the DDX3 pocket (Figure S3). The N terminus of
K7 is disordered and points away from the DDX3 pocket (a5/a6)
in the NMR models. However, the N terminus shifts toward theLtd All rights reserved
Structure
Structure of K7-DDX3DDX3 pocket in the complex, as evidenced by van der Waals
contacts between Tyr7 (K7), Phe84 (DDX3), and Phe122 (K7).
Overall, the monomeric state of K7 and its conformational flexi-
bility enables the binding of DDX3 into a deep pocket. A cartoon
depiction of DDX3 contacts with K7 is shown in Figure S4.
Mutagenesis of DDX3 and Immune Signaling
The structure of the K7-DDX3 complex implied that the dipheny-
lalanine motif of DDX3, Phe84, and Phe85 is critical for the inter-
action with K7. These two phenylalanines were mutated to
alanine to test whether this would disrupt the interaction
between DDX3 and K7. Full-length myc-tagged DDX3 (662 resi-
dues) harboring two mutations, F84A+F85A (FFAA mutant), was
cotransfected with Ha-tagged K7 into HEK293 cells, and immu-
noprecipitation experiments were performed. K7 failed to coim-
munoprecipitate with the FFAA mutant (Figure 8a, lane 6), while
in the same experiment it clearly coimmunoprecipitated with
wild-type DDX3 (Figure 8a, lane 3). These cellular assays are
consistent with in vitro thermodynamic studies in which the
FFAA mutant peptide (71–90) of DDX3 failed to demonstrate
measurable affinity with K7 by isothermal titration calorimetry
(Table 1).
After having identified residues Phe84 and Phe85 as being
essential for K7-DDX3 recognition, the functional relevance of
the diphenylalanine motif of DDX3 in the antiviral response was
investigated by immune signaling studies. In reporter-based
assays, the FFAA mutant failed to enhance IRF3 activation and
Figure 7. Superposition of K7 and A52
The DDX3 peptide (stick) occupies the position of
a6 in the Bcl-2 family. A52 dimerization is medi-
ated by its N terminus, a1 and a6, which maps
onto the DDX3 binding site of K7.
IFN-b promoter induction, whereas wild-
type DDX3 enhanced IKK3-induced sig-
nals, as described elsewhere (Schroder
et al., 2008) (Figure 8b). Altogether, our
structural and functional work suggests
a critical role for the diphenylalanine motif
of DDX3 in IRF3 activation and type I
interferon induction. In addition, these
studies suggest that K7 binding to a short
DDX3 segment encompassing the diphe-
nylalanine motif is sufficient to prevent
DDX3 from executing its role in innate
immune signaling.
DISCUSSION
The K7-DDX3 complex represents a
unique binding mode within the super-
family of Bcl-2 proteins. In effect, DDX3
occupies the position of the canonical
helix a6 and interacts with the hydro-
phobic interior of K7. Hydrophobic con-
tacts (3.6 A˚) between Phe85 (DDX3) and
Trp112 (K7 and a5) are indicative of the
depth of penetration by the diphenylalanine motif into the glob-
ular core of K7. The NMR structure of K7 revealed considerable
flexibility in the region 118–127, which is an a helix (a6) in all other
known viral and cellular Bcl-2 proteins. Furthermore, the DDX3-
binding face of K7 overlaps with the dimerization interface of
A52, its closest structural and functional relative. These data
support amodel inwhichmonomeric K7 has evolved as a confor-
mational trap for DDX3, guided by electrostatic complementarity
and anchored by the diphenylalanine motif in its hydrophobic
core. The high density of negative charges on this face likely
serves the dual function of DDX3 binding, as well as contributing
to themonomeric state of K7 via electrostatic repulsions. Several
Asp and Glu residues on this face of K7 (Asp28, Glu119, Asp130,
and Asp134) are not conserved in A52. The structure therefore
explains the specific binding of K7, but not A52, to DDX3. We
would also predict that none of the other described dimeric
Bcl-2-like VACV proteins interact with DDX3. Despite clearly
possessing Bcl-2 topology, it is not evident why a4 and a6 of
K7 are largely devoid of a-helical content. It is particularly striking
that 8 of 15 residues in a4 are identical in A52 and K7, with
conservative changes in an additional four residues. Given that
K7 and A52 share some cellular binding partners, such as
TRAF6 and IRAK2, these proteins presumably have common
epitopes elsewhere. Apart from a study showing that an A52
peptide derived from the a4-a5 loop inhibits NF-kB in isolation
(McCoy et al., 2005), there is a lack of structural and biochemical
information regarding the IRAK2 and TRAF6 binding sites.Structure 17, 1528–1537, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1533
Structure
Structure of K7-DDX3The recent determination of structures of three viral proteins
(K7,A52,andB14) that apparently fail tobindBH3domainsallows
for their comparison to canonical Bcl-2 family members. The
common structural element appears to be closure of the groove
on the C-terminal side of the BH3 helix binding site (Figure S5).
This is due to the orientation of a2, which is closer to a5 in these
three ‘‘non-BH3-binding’’ proteins. The beginning of a5 contains
the ‘‘NWGR’’ signature (BH1) motif of cellular Bcl-2 proteins,
which is lacking in the viral homologs. VACV protein N1—which
binds to the BH3 domains of Bid, Bad, and Bax—adopts an a2
orientation similar to that of K7, A52, and B14, but it is one helical
turn shorter (Figure 4), thus leaving this end of the BH3 groove
open. The pocket that accommodates the N-terminal side of
BH3 a helices displays conformational heterogeneity in the
absence of ligand among the viral and cellular proteins. This
side of the pocket is formed by a3 and a4 and is observed in
open, intermediate and closed states (Figure S5). As an example,
uncomplexed Bcl-xL adopts a ‘‘closed’’ conformation in the unli-
ganded state, which indeed describes its narrow groove
bordered by a3 and a4, relative to Bcl-2 (Petros et al., 2001; Pet-
ros et al., 2004). However, even uncomplexed Bcl-xL appears to
be more ‘‘open’’ at the a2/a5 end of the pocket.
In addition to its recently described role in innate immunity, the
biological functions ascribed to DDX3 include RNA splicing,
export, and translational regulation (Cullen, 2005; Shih et al.,
2008). In contrast to the antagonistic effect of VACV K7, other
viruses, including HCV and HIV, have been shown to co-opt
DDX3 during infection. The function of DDX3 that is targeted or
exploited by viral proteins presumably correlates with their
binding sites. The interaction between the nuclear export shuttle
protein CRM-1 and DDX3, which is co-opted by the HIV Rev
protein, has been roughly mapped to residues 260–517 of
DDX3 (Yedavalli et al., 2004). HCV core protein binding maps
to the C-terminal region of DDX3 (553–611) (Owsianka and Patel,
1999). In contrast, K7 binds to the N terminus of DDX3, and the
effect of DDX3 on innate immune signaling appears to be inde-
pendent of its RNA helicase function. A DDX3 mutant lacking
ATPase activity (K230E) retained its ability to enhance IFN-b
induction by TBK1/IKK3 (Schroder et al., 2008; Soulat et al.,
2008). Furthermore, a DDX3 truncation lacking residues 1–139
was unable to enhance IFN-b promoter induction, suggesting
that this function of DDX3 is contained within its N terminus
and correlates with the region that is targeted by the viral protein
K7 (Schroder et al., 2008).
The structural and functional data presented in this study
support a model in which K7 masks a key epitope of DDX3 that
is required for the IRF activation pathway via TBK1/IKK3. One
possibility is that the diphenylalanine motif interacts directly with
IKK3 or another effector molecule linking it to the IRF activation
pathway. A second hypothesis is that serine/threonine phosphor-
ylation of DDX3 plays a role in downstream activation and that K7
interferes with this process by masking the substrate-binding
site. The N terminus of DDX3 is enriched in serine/threonine resi-
dues (eight within the segment 71–90) that may be candidates for
phosphorylation by IKK3 or other protein kinases. These various
models canbe tested in futuremutagenesis andsignalingstudies.
Uncovering the molecular details of interactions between viral
Figure 8. Phe84 and Phe85 Are Required
for the Effect of DDX3 on the IRF Pathway
(A) HEK293Tcells were transfected with Myc-
DDX3(wild-type) or myc-FFAA mutant together
with Ha-K7 for 48 hr, and the cell lysates were
subjected to immunoprecipitation (IP) with the
indicated antibodies. The precipitated com-
plexes were analyzed by SDS-PAGE and Western
blotting (WB) with the indicated antibodies.
One representative experiment out of two is
shown.
(B and C) HEK293 cells were transfected with the
indicated amount (nanograms) of pCMV-DDX3 or
pCMV-FFAA, 25 ng of IKK3 expression plasmid,
and either the IRF3-GAL4 fusion protein in
conjunction with a GAL4-dpendent promoter or
the IFN-b promoter reporter gene. A constitutively
active Renilla luciferase construct was cotrans-
fected to control for transfection efficiency. Lucif-
erase activity was measured 36 hr after transfec-
tion. Data are expressed as the mean fold
induction ± SD relative to control levels, for an indi-
vidual experiment performed in triplicate. The first
lane in (b) and (c) is a transfection with an empty
vector (no IKK3 expression) that is normalized to control (basal) levels of transcription. A representative of at least three independent experiments is shown.
Data are shown as the mean fold induction ± SD relative to control levels, for an individual experiment performed in triplicate.
Table 1. Thermodynamics of K7 Interactions with DDX3
Fragments
DDX3 Fragment Kd (mM) DH (kcal/mol) DS (cal/mol/deg)
5–167 0.51 22 46
5–580 0.46 30 72
71–90a 0.93 26 61
81–90 1.1 22 48
81–100 1.2 15 25
71–90 (FF/AA) No binding
a Successfully crystallized in complex with full-length K7.1534 Structure 17, 1528–1537, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
Structure
Structure of K7-DDX3immune evasion proteins and their host targets may provide vital
information for the design of antivirals and immunosuppressive
drugs that mimic the strategy of the virus.
EXPERIMENTAL PROCEDURES
Expression and Purification
Escherichia coli BL21(DE3) cells were transformed with pET15 plasmid
harboring a synthetic gene encoding the full-length K7 protein (Geneart AG).
Liter volume cultures of cells were inoculated with an overnight culture and
grown in 2xYT medium (Formedium, UK). Cells were grown to mid-log phase
(OD600 = 0.6) at 310
K, and the culture was cooled in water and ice for a few
minutes. Protein expression was subsequently induced by addition of
0.2 mM IPTG (final concentration) with vigorous shaking at 298K. Following
induction for 4–6 hr, cells were harvested by centrifugation and stored frozen
if necessary at 250K.
The expression of selenomethionine-derivitized K7 followed a similar
protocol, except that a minimal media (Molecular Dimensions, UK) was used
in place of 2xYT. In addition, immediately prior to induction at mid-log phase,
the media was supplemented with amino acids Lys, Thr, and Phe (100 mg
each); Leu, Ile, and Val (50 mg each); and 50 mg of L(+)-selenomethionine.
The cells were suspended in lysis buffer (20 mM Tris-HCl [pH 8.0], 300 mM
NaCl, 10 mM imidazole, and 10 mM 2-mercaptoethanol) with a protease inhib-
itor cocktail (Roche) and were lysed using a Branson sonifier. Following centri-
fugation at 20,000 g, the soluble fraction was loaded onto a Ni2+-agarose resin
equilibratedwith lysis buffer. After successive steps ofwashingwith lysis buffer
supplemented with up to 30 mM imidazole, K7 was eluted with a step gradient
of 200mM imidazole. The eluted protein wasmixedwith thrombin (10 units/mg
of K7; GE Healthcare) to cleave the His-tag, and was dialyzed against 20 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM imidazole, and 10 mM 2-mercaptoe-
thanol. The dialyzed protein was applied to the Ni2+-agarose resin a second
time, and the flow-through fraction contained the cleaved K7 protein.
Further purification involved dialysis into a low-salt buffer (20 mM Tris-Cl
[pH 8.0], 20 mM NaCl, and 1 mM dithiothreitol), followed by anion-exchange
chromatography with a linear salt gradient to 1 M NaCl. To prepare the K7-
DDX3 peptide complex, a two-fold molar excess of peptide was added to
the affinity-purified K7 protein, just prior to ion-exchange chromatography.
Fractions containing the K7-DDX3 complex were pooled and applied to gel
filtration column (Superdex-75, GE Healthcare) equilibrated with 20 mM Tris-
HCl (pH 8.0), 150 mM NaCl, and 1 mM DTT. The final purified complex was
concentrated and subjected to crystallization procedures. All purification
procedures were performed on ice, or at 277K.
Crystallization and Structure Determination
Initial crystals were grown using the sitting drop vapor diffusion method at
291K by mixing 100 nl of protein sample at10 mg/ml and 100 nl of reservoir
solution using a Mosquito robot (TTP Labtech) in 96-well sitting drop plates.
Crystals appeared after a few days in 100 mM citrate (pH 5.5), and 20%
PEG3350. Final optimized crystals were grown in Linbro 24-well plates using
hanging drop vapor diffusion methods with a reservoir solution containing
100 mM sodium citrate (pH 5.25) and 15.0% (w/v) PEG3350. For cryoprotec-
tion, the crystals were plunged directly into mother liquor supplemented with
20% (w/v) xylitol. Diffraction data at the selenium peak (0.979 A˚) were collected
at beamline BM14 at the European Synchrotron Radiation Facility (ESRF) in
Grenoble, France. Data were integrated and scaled with DENZO/SCALEPACK
package (Otwinowski and Minor, 1997). The structure of the K7-DDX3 peptide
complex was solved by SAD methods. Five of six expected selenium sites
were found using ShelxD, and density modification was performed using
ShelxE (Sheldrick, 2008). The resulting map was readily interpretable, and
continuous backbone density of K7 between Tyr7 to Asn149 could be traced
with COOT (Emsley andCowtan, 2004). In parallel, model building was initiated
with ArpWarp 7.0.1 (Perrakis et al., 2001), which resulted in automated place-
ment of 272 of 300 residues of K7 (dimer in the asymmetric unit). The remaining
K7 residues and the DDX3 peptide were manually built by alternating cycles of
model building with COOT (Emsley and Cowtan, 2004) and refinement using
Refmac5 (Murshudov et al., 1997). Subsequent iterative model improvement
and refinement were performed with COOT and Refmac5. There are twoStructure 17, 1528–15K7-DDX3 complexes in the asymmetric unit, and residues Ser82-Arg88 of
DDX3 are well-defined and identical in conformation for both complexes.
The rmsd for all atoms in the two complexes is 0.93 A˚. The rmsd for K7 atoms
is 0.94 A˚, whereas the rmsd for equivalent DDX3 peptide atoms is 0.10 A˚.
However, terminal residues Lys81 and Gly89 of DDX3 are poorly defined
and disordered. The sixth SeMet residue was situated in a flexible loop
(Met80) in molecule A, thus explaining its poor contribution to the anomalous
signal, and was built into the model in later refinement cycles. The initial elec-
tron density map from ShelxE is shown together with the final refined model of
K7-DDX3 in order to highlight the quality of SAD data (Figure S6). A Ramachan-
dran plot maps 97.9% of residues in the preferred regions, and only one
residue (Ser118) lies slightly outside the generous a-helical conformational
space. The data and refinement statistics are summarized in Table 2.
Isothermal Titration Calorimetry
Calorimetric measurements were performing using the ITC-200 instrument
(MicroCal, Inc). Purified K7 (alone) was dialyzed against 10 mM Tris-Cl
Table 2. Data Collection and Refinement Statistics
SeMet (Peak Data)
Data collection
Space group C2
Cell dimensions
a, b, c (A˚) 90.89, 69.53, 65.63
a, b, g () 90.00, 122.17, 90.00
Resolution (A˚) 30–1.60 (1.66–1.60)a
Rsym 0.081 (0.373)
I / sI 35.4 (3.39)
Completeness (%) 97.3 (84.9)
Redundancy 7.0 (4.6)
Shelx D/E phasing
SeMet sites 5
CC all/weak 47.46/34.15
PATFOM 44.09
Pseudo-free CC 77.92%
Connectivity 0.937
Refinement
Resolution (A˚) 30.0–1.60
No. of reflections 45370 (2267)
Rwork / Rfree (%) 14.1/18.9
No. atoms
K7 2316
DDX3 peptide 160
Water 251
B-factors
K7 all atoms 17.2
K7 main chain 15.0
K7 side chain 19.4
DDX3 all atoms 19.6
DDX3 main chain 17.8
DDX3 side chain 21.4
Water 28.4
Rmsds
Bond lengths (A˚) 0.0146
Bond angles () 1.497
a Values in parentheses are for highest-resolution shell.37, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1535
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Structure of K7-DDX3(pH 7.5), 100mMNaCl, and 1mMDTT. Following dialysis and concentration of
the protein to approximately 60 mM, the flow-through buffer from the concen-
trator (iCON, Pierce Inc) was used to directly solubilize the pure peptide (lyoph-
ilized powder; EMC Microcollections GmbH) to give a final concentration of
600 mM. This strategy minimized the buffer mismatch in the subsequent titra-
tions. The same buffer was used to dilute K7 and the DDX3 peptides to obtain
ideal concentrations for binding isotherms suitable for subsequent data anal-
yses. Titrations were performed at 293K with K7 in the reference cell and
peptide in the injection cell. The concentrations varied from 250 to 400 mM
for the peptide and from 20 to 50 mM for K7 protein. For the titration involving
the nearly complete fragment of DDX3 (5–580), K7 was loaded into the injec-
tion syringe, and DDX3 was placed in the cell. Data analyses by peak integra-
tion and curve fitting were performed using the Origin software 7.0, and curves
were fit to a single-site binding model to give the binding constant (Kd),
enthalpy change (DH), and entropy (DS) of complex formation.
Mutagenesis and Cellular Studies
The F84A and F85A mutations were simultaneously introduced into the DDX3
sequence by PCR using the previously described pCMV-myc DDX3 construct
(Schroder et al., 2008) as a template and Pfusion DNA polymerase (New
England Biolabs). Coimmunoprecipitations were performed as described
elsewhere (Stack et al., 2005). In brief, Ha-tagged K7 and myc-tagged DDX3
or FFAA were cotransfected into HEK293T cells, cells were harvested 48 hr
after transfection, and cell lysates were prepared. Antibodies were precoupled
to Protein G-Sepharose beads (Sigma) and then were used to immunoprecip-
itate proteins from cell lysates. Immunocomplexes were analyzed by SDS-
PAGE and Western blotting with anti-Ha (Covance) and anti-myc antibodies
(Sigma). Promoter induction and transcription factor activation weremeasured
using HEK293 cells seeded onto 96-well plates and were transfected 24 hr
later with expression vectors and luciferase reporter genes (Maloney et al.,
2005; Schroder et al., 2008; Stack et al., 2005). IRF3 activation was measured
using a fusion protein between the DNA-binding domain of the yeast transcrip-
tion factor GAL4 and IRF3 in conjunction with a GAL4-responsive reporter
gene construct. Data are expressed as the mean fold induction ± SD relative
to control levels, for an individual experiment performed in triplicate. A repre-
sentative of at least three independent experiments is shown.
ACCESSION NUMBERS
The structure of K7-DDX3 peptide has been deposited in the Protein Data
Bank with the accession code 3JRV.
SUPPLEMENTAL DATA
Supplemental data include six figures and one movie and may be found
with this article online at http://www.cell.com/structure/supplemental/
S0969-2126(09)00371-2.
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